BioSpace News Archive

Company restructuring efforts continue to gain traction towards profitability.

PARADIGME is designed to generate the clinical data needed to support the filing of the best Betalutin dosage regimen for this patient population.

AdapTEK allows a surgeon to create a range of interbody devices to their individual specifications that are then produced by Medicrea with complete in-house additive manufacturing capabilities and total control of the internal process without any of the limitations associated with subcontracting external suppliers.

The redemption was made at an amount corresponding to 101 percent of the nominal amount together with accrued but unpaid interest from the preceding interest payment date on November 9 2017 up to, and including, the redemption date on November 22 2017.

he website provides patients and their caregivers with helpful information on Debiopharm’s clinical trials and studies.

Khondrion today announced results from its KHENERGY study, a Phase II exploratory trial with oral KH176 in the m.3243A>G multisystem mitochondrial MELAS and MIDD syndromes and mixed phenotypes.

Mundipharma will have exclusive rights to the product in more than 35 African markets and countries.

Cellect Biotech today provided a corporate update and announced financial results for the third quarter ended September 30, 2017.

The data confirmed no significant safety issues and that efficacy appeared to be comparable to existing commercial IVIG products.

The study’s results demonstrated an enhanced T cell expansion, activation, and antigen-specific killing of GBM tumor cells with use of the full-length LAMP-1 pp65 chimeric RNA pulsed DCs.